플러스 테라퓨틱스(PSTV)는 NASDAQ에 상장된 Healthcare · Biotechnology 기업입니다. 현재가 $2.03 (-0.49%), 시가총액 $0.04B, 52주 최저~최고 $0.16 ~ $7.62.
Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. The company's lead radiotherapeutic candidate is rhenium obisbemeda, a patented radiotherapy for patients with central nervous system and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. It also develops Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere to treat various solid organ cancers, such as primary and secondary liver cancers by intra-arterial injection. In addition, it develops and commercializes laboratory-developed tests comprising the CNSide Test to
플러스 테라퓨틱스의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 BlackAll Trade에서 실시간으로 확인할 수 있습니다.
플러스 테라퓨틱스의 현재 주가는 $2.03 (-0.49%)입니다. BlackAll Trade에서 실시간 시세와 차트를 확인할 수 있습니다.
플러스 테라퓨틱스의 시가총액은 약 $0.04B입니다.
Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. The company's lead radiotherape